PSPriya Singhal

Priya Singhal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Priya Singhal has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development and Evaluation of a Baicalin-Loaded Phytosomal Transdermal Patch for Type 2 Diabetes Mellitus

    by Priya Singhal, Rupa Mazumder, Anjna Rani, Abhijit Debnath

    Introduction: Type 2 diabetes management remains challenging because of low bioavailability, side effects, and poor compliance with oral therapies. Transdermal delivery methods offer a non-invasive therapeutic approach with sustained delivery, which avoids first-pass metabolism. Methods: A total of 207 different phytochemicals were virtually screened using i-dock against the diabetic target, PPAR-γ. Subsequently, three matrix-type transdermal patches were developed: a patch containing pure baicalin, a standard patch containing metformin, and a baicalin-loaded phytosomal patch. Phytosomes loaded with baicalin were optimized by using Central Composite Design and evaluated for their physicochemical properties, drug content, physical strength, in vitro, and ex vivo studies. In vivo antidiabetic efficacy was also studied in diabetic Wistar rats over 21 days, followed by a comparison of all formulations, including histopathological analysis of pancreatic tissue. Results: Molecular docking studies showed promising results; baicalin has a high binding affinity for PPAR-γ (-9.8 kcal/mol). The optimized phytosomal patch confirmed a uniform drug content (91.4 ± 0.12 %) and showed sustained release over 12 hours. The ex vivo permeation study showed a significantly higher skin flux for the phytosomal patch (83.6%). In vivo studies confirmed that baicalin-loaded phytosomal patches showed significant blood glucose reductions (223 ± 0.32 to 96 ± 0.38 levels by Day 21), a comparable efficacy to standard metformin patches (224 ± 0.37mg/dL to 94 ± 0.34 mg/dL by Day 21). Discussion: The enhanced skin permeation, penetration, and sustained-release exhibited by the phytosomal transdermal patch can be explained by the phospholipid-based shell structure, leading to better affinity with the skin, facilitating retention of the drug. The comparable glycemic control observed with metformin indicates that baicalin-loaded phytosomal transder-mal patches can achieve effective therapeutic concentrations via transdermal delivery, which is corroborated across two studies. These observations are consistent with previous literature documenting improved solubility and bioavailability of plant-derived actives utilizing phyto-some-based systems, which have applicability for chronic metabolic diseases such as T2DM. Conclusion: The developed phytosomal transdermal patch showed sustained release, better permeation, and potent antidiabetic activity; thus, it offers an alternative to conventional T2DM therapies.


  • Emerging Multi-Target Therapies for Type 2 Diabetes: Bridging Drug Innovation and Precision Delivery

    by Priya Singhal, Rupa Mazumder, Anjna Rani, Abhijit Debnath

    Diabetes is a long-term metabolic disorder characterized by elevated blood glucose levels and is primarily classified into Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM). Conventional drug delivery systems often face limitations such as low bioavailability, inadequate target specificity, and the need for frequent dosing. Drug targeting offers significant advantages in diabetes treatment by enhancing therapeutic efficacy and reducing side effects. This is achieved by binding drug-loaded carriers to specific receptors on insulin-sensitive tissues or pancreatic β-cells, ensuring precise action at the disease site and improving patient compliance. Several therapeutic targets have been identified to improve glycemic control and overcome the limitations associated with traditional drug delivery approaches. The present study provides insights into emerging targets for diabetes management, including AMPK (AMP-Activated Protein Kinase), glucose absorption inhibitors, renal glucose reabsorption inhibitors, GLP-1 (Glucagon- Like Peptide-1) agonists, SGLT2 (Sodium-Glucose Cotransporter-2) inhibitors, and PPAR-γ (Peroxisome Proliferator-Activated Receptor Gamma) modulators. Increasing attention is also being given to multi-targeted therapy, which simultaneously modulates multiple interconnected physiological pathways involved in diabetes pathogenesis. Such strategies have demonstrated the potential to improve glycemic control, reduce long-term complications, and offer better safety profiles compared to monotherapy. Given the multifactorial nature of diabetes, a combination of precisionbased and multi-targeted approaches holds promise for developing safer, better tolerated, and patient- centered antidiabetic therapies. This review highlights recent advances in identifying novel therapeutic targets and drug delivery strategies, contributing to the evolving paradigms that may shape the future of diabetes care.


  • Development of Transdermal Drug Delivery Approaches to Combat Diabetes: An Update

    by Priya Singhal, Rupa Mazumder, Anjna Rani, Abhijit Debnath

    Background: Diabetes mellitus, a widespread and chronic metabolic condition, creates signif-icant challenges for healthcare systems due to complications from inadequate glycemic control, patient non-compliance, and the invasive nature of traditional treatments, including oral medications and insulin injections, which often lead to discomfort, variability in blood glucose levels, and low adherence. Objective: To explore the potential of Transdermal Drug Delivery Systems (TDDS) as a non-invasive and effective alternative for diabetes management, highlighting their advantages, recent technological ad-vancements, and associated challenges. Methods: This review examines the role of TDDS in diabetes treatment, with an emphasis on recent in-novations, including microneedles, hydrogels, and sonophoresis. The study also discusses the benefits of TDDS in maintaining stable plasma drug levels, reducing first-pass metabolism, and integrating with con-tinuous glucose monitoring systems. Results: Emerging TDDS technologies improve drug permeability, enhance bioavailability, and offer sus-tained drug release, potentially addressing limitations of conventional delivery methods. However, barri-ers such as skin permeability, high manufacturing costs, and patient variability remain significant chal-lenges. Conclusion: TDDS presents a promising alternative for diabetes management by improving patient ad-herence, ensuring controlled drug release, and reducing discomfort associated with injections. While fur-ther research is required to overcome existing limitations, advancements in biomaterials and personalized medicine approaches hold the potential to optimize TDDS for widespread clinical application. This re-search aims to summarize the advancements and address existing challenges for future development.